Lupin ropes in Diana Amador-Toro as Senior Vice President, Global Compliance
Diana Amador-Toro will be based in Lupin's Somerset office in New Jersey, USA.
Mumbai: Global pharma major Lupin Limited has announced the appointment of Diana Amador-Toro as Senior Vice President, Global Compliance.
Diana will be responsible for leading Lupin's Global Compliance function including Training, Internal Audit, and Investigations. She will be based in Lupin's Somerset office in New Jersey, USA. Diana is a senior leader with more than 38 years of field experience in U.S. FDA's Office of Regulatory Affairs (ORA). She previously served in two leadership positions in ORA as the New Jersey District Director and as the Office of Pharmaceutical Quality Operations Division I Director.
In these roles, she provided executive leadership in directing and managing FDA pharmaceutical inspectional and compliance activities. She has been recognized with numerous awards, including the USFDA Commissioner's Special Citation and FDA's highest award, the Award of Merit.
Commenting on the appointment, Vinita Gupta, Chief Executive Officer and Nilesh Gupta, Managing Director, Lupin said, "Quality is one of the most critical pillars of our organization, and we are delighted to have a leader with Diana's experience and track record of excellence come on board. We are confident that Diana's passion for quality and developing talent will make a significant difference in our efforts to achieve the highest standards of quality and compliance."
Read also: Flutura accelerates Lupin to digitally transform their operations using AI
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas.
Rea
d also: Lupin gets USFDA nod for generic equivalent of Vemlidy Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.